Vivani completes dosing in 20-participant NPM-139 trial
Vivani Medical announced successful dosing of all SLIM-1 trial participants, evaluating its NPM-139 implant ahead of schedule. With data expected in 2026, this advance follows a recent partnership with Novo Nordisk.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day